DYDC2 Activators
The activation of DYDC2 is a process that can be influenced by a variety of intracellular signaling mechanisms, which may involve changes in the phosphorylation state of the protein. This can be initiated by compounds that elevate intracellular cyclic AMP (cAMP) levels, thereby activating protein kinase A (PKA). PKA is known to phosphorylate a wide range of substrates, and it is through this kinase's activity that DYDC2 may be phosphorylated and activated. Furthermore, the use of specific phosphodiesterase inhibitors plays a pivotal role in sustaining elevated levels of cAMP by preventing its degradation, which in turn sustains PKA activity and promotes the continued activation of DYDC2. Additionally, the activation of protein kinase C (PKC) represents another pathway by which DYDC2 may be activated. PKC is known to directly phosphorylate substrates, and it is plausible that through PKC-mediated phosphorylation events, the activity of DYDC2 is increased. This mechanism is complemented by the influence of calcium ionophores, which by increasing intracellular calcium concentrations, can activate calcium-dependent kinases with the potential to phosphorylate and activate DYDC2.
In addition to these pathways that involve modulation of phosphorylation through kinase activity, there are alternate routes by which DYDC2 activation can be achieved. The inhibition of protein phosphatases, which normally serve to dephosphorylate proteins, can result in a net increase in the phosphorylation state of proteins including DYDC2. This is due to the sustained phosphorylation that occurs when phosphatase activity is reduced. Furthermore, cellular stress responses can also lead to the activation of stress-activatedprotein kinases that may target and enhance the activity of DYDC2. In addition, the use of specific kinase inhibitors can have paradoxical effects; for instance, inhibiting one pathway may lead to compensatory activation of alternative pathways that could result in the activation of DYDC2. This can be observed with inhibitors of the phosphoinositide 3-kinases (PI3K), which by disrupting downstream AKT signaling, may affect the phosphorylation status of a multitude of proteins, potentially including DYDC2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylyl cyclase leading to an increase in cyclic AMP (cAMP) levels, which may enhance the PKA-mediated phosphorylation of DYDC2, thereby increasing its activity. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
A synthetic catecholamine and beta-adrenergic agonist that increases intracellular cAMP, potentially contributing to PKA activation and subsequent phosphorylation of target proteins including DYDC2. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
A non-selective inhibitor of phosphodiesterases, increases cAMP levels by preventing its degradation, which may stimulate PKA activity and phosphorylation of DYDC2. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates protein kinase C (PKC) which could phosphorylate DYDC2 directly or modulate signaling pathways that lead to its activation. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
A calcium ionophore that increases intracellular calcium concentration, potentially activating calcium-dependent kinases which could phosphorylate and activate DYDC2. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A calcium ionophore that raises intracellular calcium levels, potentially influencing calcium-dependent signaling pathways resulting in the activation of DYDC2. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
A cAMP analog resistant to degradation by phosphodiesterases, which may activate PKA and promote phosphorylation of proteins including DYDC2. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
A phosphodiesterase 5 inhibitor that increases cAMP levels in certain cells, potentially enhancing PKA activity and phosphorylation of target proteins such as DYDC2. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
A selective phosphodiesterase 4 inhibitor that elevates intracellular cAMP, which could lead to the activation of PKA and subsequent phosphorylation and activation of DYDC2. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Acts as a protein synthesis inhibitor, which induces stress responses and could activate stress-activated protein kinases that may phosphorylate and activate DYDC2. | ||||||